These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 16280113)

  • 21. Erythropoietic agents in chemotherapy-induced anemia: a review of recent therapeutic progress, issues, and concerns.
    Boccia RV
    Curr Hematol Rep; 2004 Nov; 3(6):397-405. PubMed ID: 15496272
    [TBL] [Abstract][Full Text] [Related]  

  • 22. FDA finalizes REMS program for ESAs; Amgen continues to study risks.
    Brower V
    J Natl Cancer Inst; 2010 May; 102(9):592-3. PubMed ID: 20421565
    [No Abstract]   [Full Text] [Related]  

  • 23. A randomized, active-control, pilot trial of front-loaded dosing regimens of darbepoetin-alfa for the treatment of patients with anemia during chemotherapy for malignant disease.
    Waltzman RJ
    Cancer; 2004 Apr; 100(7):1545-6; author reply 1546. PubMed ID: 15042691
    [No Abstract]   [Full Text] [Related]  

  • 24. Epoetin alfa versus darbepoetin alfa in chemotherapy-related anemia.
    Cersosimo RJ; Jacobson DR
    Ann Pharmacother; 2006 Jan; 40(1):58-65; quiz 169-70. PubMed ID: 16332942
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anemia in cancer: update on studies of erythropoiesis-stimulating agents.
    Burstein HJ
    J Support Oncol; 2007 Apr; 5(4 Suppl 2):5-26. PubMed ID: 17550053
    [No Abstract]   [Full Text] [Related]  

  • 26. Warning flags for erythropoiesis-stimulating agents and cancer-associated anemia.
    Lappin TR; Maxwell AP; Johnston PG
    Oncologist; 2007 Apr; 12(4):362-5. PubMed ID: 17470677
    [No Abstract]   [Full Text] [Related]  

  • 27. Clinical use of erythropoietic stimulating agents in myelodysplastic syndromes.
    Santini V
    Oncologist; 2011; 16 Suppl 3():35-42. PubMed ID: 21930833
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biosimilar epoetins.
    Macdougall IC
    Nephrol Dial Transplant; 2009 May; 24(5):1698-9; author reply 1699-700. PubMed ID: 19366858
    [No Abstract]   [Full Text] [Related]  

  • 29. Darbepoetin alfa in the treatment of anemia in cancer patients undergoing chemotherapy.
    Wauters I; Vansteenkiste J
    Expert Rev Anticancer Ther; 2012 Nov; 12(11):1383-90. PubMed ID: 23113603
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia: the 20030125 Study Group Trial.
    ; Glaspy J; Vadhan-Raj S; Patel R; Bosserman L; Hu E; Lloyd RE; Boccia RV; Tomita D; Rossi G
    J Clin Oncol; 2006 May; 24(15):2290-7. PubMed ID: 16710026
    [TBL] [Abstract][Full Text] [Related]  

  • 31. September 2007 update on EORTC guidelines and anemia management with erythropoiesis-stimulating agents.
    Aapro MS; Link H
    Oncologist; 2008; 13 Suppl 3():33-6. PubMed ID: 18458123
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Consensus on the Existence of Functional Erythropoietin Receptors on Cancer Cells.
    Bennett CL; Lai SY; Sartor O; Georgantopoulos P; Hrushesky WJ; Henke M; Armitage JO
    JAMA Oncol; 2016 Jan; 2(1):134-6. PubMed ID: 26606114
    [No Abstract]   [Full Text] [Related]  

  • 33. Dosing patterns, hematologic outcomes, and costs of erythropoietic agents in anemic predialysis chronic kidney disease patients from an observational study.
    Papatheofanis F; Smith C; Mody S; McKenzie RS; Bookhart B; Piech CT
    Am J Ther; 2007; 14(4):322-7. PubMed ID: 17667204
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Parenteral iron with erythropoiesis-stimulating agents for chemotherapy-induced anemia.
    Shord SS; Hamilton JM; Cuellar S
    J Oncol Pharm Pract; 2008 Mar; 14(1):5-22. PubMed ID: 18337436
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ESAs further restricted, but debate continues.
    Brower V
    J Natl Cancer Inst; 2008 Oct; 100(19):1344-51. PubMed ID: 18812542
    [No Abstract]   [Full Text] [Related]  

  • 36. A randomized, open-label, multicenter trial of immediate versus delayed intervention with darbepoetin alfa for chemotherapy-induced anemia.
    Charu V; Saidman B; Ben-Jacob A; Justice GR; Maniam AS; Tomita D; Rossi G; Rearden T; Glaspy J
    Oncologist; 2007 Oct; 12(10):1253-63. PubMed ID: 17962619
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Anemia in patients with cancer].
    Kobune M; Kato J; Niitsu Y
    Nihon Rinsho; 2008 Mar; 66(3):524-9. PubMed ID: 18330028
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An ongoing study of anemia correction in chronic kidney disease.
    Pfeffer MA;
    N Engl J Med; 2007 Mar; 356(9):959-61. PubMed ID: 17329707
    [No Abstract]   [Full Text] [Related]  

  • 39. Chemotherapy-induced anemia.
    Miller CB
    Contrib Nephrol; 1991; 88():248-51; discussion 252-3. PubMed ID: 2040186
    [No Abstract]   [Full Text] [Related]  

  • 40. Does TREAT give the boot to ESAs in the treatment of CKD anemia?
    Singh AK
    J Am Soc Nephrol; 2010 Jan; 21(1):2-6. PubMed ID: 20035034
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.